CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
December 12, 2018
For Release: Immediately
to: Mark Taylor; firstname.lastname@example.org; (317) 276-5795 (Lilly Media)
Hern; email@example.com; (317) 277-1838 (Lilly Investors)
Gallagher; firstname.lastname@example.org; 312-792-3937 (ACI Media US)
Dr. David Lowe; email@example.com;
+41 79 281 6494 (ACI Corporate-EU)
Sher; firstname.lastname@example.org; (970) 987-2654 (ACI Investors)
and AC Immune Announce License and Collaboration Agreement
agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment
of Alzheimer’s disease and other neurodegenerative diseases.|
Immune to receive an initial upfront payment of CHF80 million and will be eligible for
CHF60 million in potential near-term development milestones, up to approximately CHF1.7
billion in other potential development, regulatory and commercial milestones, and low
double-digit royalties. |
to purchase $50 million note, convertible to equity position in AC Immune.|
INDIANAPOLIS, IN and LAUSANNE,
SWITZERLAND — Eli Lilly and Company (NYSE:LLY) and AC Immune SA (NASDAQ: ACIU) today announced that the two companies have
signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential
treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. The collaboration combines AC Immune’s
proprietary MorphomerTM platform technology with Lilly’s clinical development expertise and commercial capabilities
in central nervous system disorders. The collaboration will focus primarily on AC Immune’s lead molecule, ACI-3024, which
has demonstrated tau aggregation inhibition in preclinical models.
Under the terms of the agreement,
AC Immune will receive an upfront payment of CHF80 million as well $50 million in exchange for a note, convertible to equity at
a premium. AC Immune is also eligible to receive CHF60 million in potential near-term development milestones, as well as other
potential development, regulatory and commercial milestones up to approximately CHF1.7 billion, and tiered royalty payments in
the low double digits.
AC Immune will conduct the initial
Phase 1 development of the Morphomer tau aggregation inhibitors, while Lilly will fund and conduct further clinical development.
Lilly will receive worldwide commercialization rights
for the tau aggregation inhibitors in the area of Alzheimer’s disease. AC Immune has retained certain development rights
in orphan indications and co-development and co-promotion options in certain indications outside AD.